
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5509696/publications.pdf Version: 2024-02-01



KWUN M FONG

#	Article	lF	CITATIONS
1	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2005, 97, 339-346.	6.3	2,194
2	Somatic Mutations of the <i>HER2</i> Kinase Domain in Lung Adenocarcinomas. Cancer Research, 2005, 65, 1642-1646.	0.9	641
3	<i>PIK3CA</i> Mutations and Copy Number Gains in Human Lung Cancers. Cancer Research, 2008, 68, 6913-6921.	0.9	399
4	Molecular Genetics of Lung Cancer. Annual Review of Medicine, 2003, 54, 73-87.	12.2	289
5	Inhaled corticosteroids for stable chronic obstructive pulmonary disease. The Cochrane Library, 2016, 2016, CD002991.	2.8	281
6	Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. International Journal of Cancer, 2003, 103, 153-160.	5.1	273
7	Respiratory health effects of diesel particulate matter. Respirology, 2012, 17, 201-212.	2.3	247
8	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. PLoS Medicine, 2006, 3, e486.	8.4	228
9	An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. Cancer Research, 2005, 65, 4031-4040.	0.9	206
10	Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 1998, 17, 1557-1565.	5.9	181
11	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
12	Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 2013, 5, E254-307.	1.4	170
13	Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. , 1998, 21, 308-319.		158
14	Progress in understanding the molecular pathogenesis of human lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 1998, 1378, F21-F59.	7.4	147
15	Molecular pathogenesis of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 1136-1152.	0.8	119
16	Biomarkers of progression of chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2014, 6, 1532-47.	1.4	111
17	Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma. Clinical Cancer Research, 2007, 13, 2946-2954.	7.0	107
18	Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, , CD002991.		103

#	Article	IF	CITATIONS
19	MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e12560.	2.5	100
20	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene, 2003, 22, 1580-1588.	5.9	98
21	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Chest, 2020, 158, 406-415.	0.8	95
22	Psychological distress and quality of life in lung cancer: the role of healthâ€related stigma, illness appraisals and social constraints. Psycho-Oncology, 2015, 24, 1569-1577.	2.3	92
23	Molecular biology of lung cancer: Clinical implications. Clinics in Chest Medicine, 2002, 23, 83-101.	2.1	90
24	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 344-359.	1.1	87
25	Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1513-1527.	1.1	83
26	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	7.0	81
27	Arg389Gly-β1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics, 2007, 17, 941-949.	1.5	78
28	Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 439-456.	3.4	77
29	MicroRNA-34c is associated with emphysema severity and modulates SERPINE1 expression. BMC Genomics, 2014, 15, 88.	2.8	76
30	Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. Journal of Thoracic Disease, 2019, 11, S2155-S2172.	1.4	76
31	The role of Toll-like receptors and related receptors of the innate immune system in asthma. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 23-28.	2.3	75
32	Electromagnetic navigation bronchoscopy: A descriptive analysis. Journal of Thoracic Disease, 2012, 4, 173-85.	1.4	75
33	Meta- and Pooled Analysis of GSTP1 Polymorphism and Lung Cancer: A HuGE-GSEC Review. American Journal of Epidemiology, 2009, 169, 802-814.	3.4	73
34	Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO <sub>m2012</sub> risk prediction tool. International Journal of Cancer, 2017, 141, 242-253.	5.1	73
35	p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer, 2004, 100, 1673-1682.	4.1	72
36	Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene, 2006, 25, 959-968.	5.9	72

#	Article	IF	CITATIONS
37	Genomics and the respiratory effects of air pollution exposure. Respirology, 2012, 17, 590-600.	2.3	70
38	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis, 2013, 34, 513-521.	2.8	67
39	Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthmaâ~†. Journal of Allergy and Clinical Immunology, 2004, 113, 889-895.	2.9	66
40	USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening) Tj ETQ	9000101gB	T /Overlock 10
41	Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology, 2011, 7, 737-752.	2.4	61
42	Protocol and Rationale for the International Lung Screening Trial. Annals of the American Thoracic Society, 2020, 17, 503-512.	3.2	56
43	Epigenetics of lung cancer. Respirology, 2006, 11, 355-365.	2.3	52
44	Conservation of the cardiostimulant effects of (â^')-norepinephrine across Ser49Gly and Gly389Arg beta1-adrenergic receptor polymorphisms in human right atrium in vitro. Journal of the American College of Cardiology, 2002, 40, 1275-1282.	2.8	51
45	Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study. Lung Cancer, 2018, 124, 199-204.	2.0	51
46	Abnormalities of Fragile Histidine Triad Genomic and Complementary DNAs in Cervical Cancer: Association With Human Papillomavirus Type. Journal of the National Cancer Institute, 1998, 90, 433-439.	6.3	49
47	(-)-CCP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the l²1-adrenoceptor. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 10-21.	3.0	49
48	Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene, 2005, 24, 6249-6255.	5.9	49
49	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	1.1	49
50	Genetic susceptibility to lung cancer and co-morbidities. Journal of Thoracic Disease, 2013, 5 Suppl 5, S454-62.	1.4	49
51	Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non-small cell lung cancer. Genes Chromosomes and Cancer, 1994, 10, 183-189.	2.8	48
52	Myeloperoxidase G-463A polymorphism and lung cancer: A HuGE Genetic Susceptibility to Environmental Carcinogens pooled analysis. Genetics in Medicine, 2007, 9, 67-73.	2.4	47
53	Gene–environmental interaction in asthma. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 75-82.	2.3	46
54	Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural	2.6	46

effusions including mesotheliomas. BMC Cancer, 2012, 12, 428. 54 iigi

#	Article	IF	CITATIONS
55	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 2018, 2018, CD006847.	2.8	44
56	Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. Journal of Thoracic Disease, 2014, 6, 1586-96.	1.4	42
57	Screening for lung cancer with low-dose computed tomography: a review of current status. Journal of Thoracic Disease, 2013, 5 Suppl 5, S524-39.	1.4	41
58	Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. The Cochrane Library, 2015, 2015, CD006849.	2.8	39
59	Frequent Loss of KAI1 Expression in Squamous and Lymphoid Neoplasms. American Journal of Pathology, 1999, 154, 1665-1671.	3.8	36
60	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	1.8	36
61	Expression profiling identifies genes involved in emphysema severity. Respiratory Research, 2009, 10, 81.	3.6	35
62	Brief Tailored Smoking Cessation Counseling in a Lung Cancer Screening Population is Feasible: A Pilot Randomized Controlled Trial: Table 1 Nicotine and Tobacco Research, 2016, 18, 1665-1669.	2.6	35
63	Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. , 2008, , CD006849.		33
64	A retrospective study of volume doubling time in surgically resected nonâ€small cell lung cancer. Respirology, 2014, 19, 755-762.	2.3	33
65	Is tissue still the issue in detecting molecular alterations in lung cancer?. Respirology, 2020, 25, 933-943.	2.3	31
66	TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene, 1998, 17, 1141-1148.	5.9	30
67	Epigenomic targets for the treatment of respiratory disease. Expert Opinion on Therapeutic Targets, 2009, 13, 625-640.	3.4	30
68	Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia. Journal of Thoracic Oncology, 2018, 13, 1094-1105.	1.1	29
69	Array-Comparative Genomic Hybridization Reveals Loss of SOCS6 Is Associated with Poor Prognosis in Primary Lung Squamous Cell Carcinoma. PLoS ONE, 2012, 7, e30398.	2.5	28
70	Whole genome sequencing for lung cancer. Journal of Thoracic Disease, 2012, 4, 155-63.	1.4	28
71	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters, 2015, 10, 1775-1782.	1.8	27
72	A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. BMJ Open, 2017, 7, e018100.	1.9	27

#	Article	IF	CITATIONS
73	MS4A1 Dysregulation in Asbestos-Related Lung Squamous Cell Carcinoma Is Due to CD20 Stromal Lymphocyte Expression. PLoS ONE, 2012, 7, e34943.	2.5	27
74	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. Oncotarget, 2015, 6, 394-408.	1.8	27
75	Genes and Gene Ontologies Common to Airflow Obstruction and Emphysema in the Lungs of Patients with COPD. PLoS ONE, 2011, 6, e17442.	2.5	26
76	'Iron lung': Distinctive bronchoscopic features of acute iron tablet aspiration. Respirology, 2003, 8, 541-543.	2.3	25
77	Validation of the Eighth Edition TNM Lung Cancer Staging System. Journal of Thoracic Oncology, 2020, 15, 649-654.	1.1	25
78	Precise localization of theFHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affectFHIT transcription in tumor cell lines. , 1997, 20, 16-23.		24
79	<i>ADAM28</i> : A potential oncogene involved in asbestosâ€related lung adenocarcinomas. Genes Chromosomes and Cancer, 2010, 49, 688-698.	2.8	24
80	The effectiveness of lung cancer <scp>MDT</scp> and the role of respiratory physicians. Respirology, 2015, 20, 884-888.	2.3	24
81	Lung cancer screening feasibility in Australia. European Respiratory Journal, 2015, 45, 1734-1737.	6.7	24
82	Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis, 2019, 40, 724-734.	2.8	24
83	E-cigarettes induce toxicity comparable to tobacco cigarettes in airway epithelium from patients with COPD. Toxicology in Vitro, 2021, 75, 105204.	2.4	24
84	The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. Respirology, 2012, 17, 247-260.	2.3	23
85	Phenotypes and Karyotypes of Human Malignant Mesothelioma Cell Lines. PLoS ONE, 2013, 8, e58132.	2.5	23
86	Nonâ€small cell lung cancer brain metastasis screening in the era of positron emission tomographyâ€ <scp>CT</scp> staging: Current practice and outcomes. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 383-388.	1.8	23
87	Air pollution in the Asiaâ€Pacific Region. Respirology, 2019, 24, 484-491.	2.3	23
88	Effectiveness of Hospital-Based Smoking Cessation. Chest, 2005, 128, 216-223.	0.8	22
89	Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process. Respirology, 2018, 23, 927-934.	2.3	22
90	Lung Cancer Stigma across the Social Network: Patient and Caregiver Perspectives. Journal of Thoracic Oncology, 2018, 13, 1443-1453.	1.1	22

#	Article	lF	CITATIONS
91	An emerging place for lung cancer genomics in 2013. Journal of Thoracic Disease, 2013, 5 Suppl 5, S491-7.	1.4	22
92	Mediastinal Abscess After Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Journal of Bronchology and Interventional Pulmonology, 2013, 20, 338-341.	1.4	21
93	Inhaled corticosteroids for subacute and chronic cough in adults. The Cochrane Library, 2013, 2013, CD009305.	2.8	20
94	Coronary Artery Calcification on Computed Tomography Correlates With Mortality in Chronic Obstructive Pulmonary Disease. Journal of Computer Assisted Tomography, 2014, 38, 753-759.	0.9	19
95	Plasma Extracellular Vesicle miRNAs Can Identify Lung Cancer, Current Smoking Status, and Stable COPD. International Journal of Molecular Sciences, 2021, 22, 5803.	4.1	19
96	Screen-detected subsolid pulmonary nodules: long-term follow-up and application of the PanCan lung cancer risk prediction model. British Journal of Radiology, 2016, 89, 20160016.	2.2	18
97	Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. Lung Cancer, 2011, 72, 213-218.	2.0	17
98	Indigenous Respiratory Outreach Care: the first 18 months of a specialist respiratory outreach service to rural and remote Indigenous communities in Queensland, Australia. Australian Health Review, 2014, 38, 447.	1.1	17
99	Fineâ€needle aspiration diagnosis of sclerosing hemangioma (pneumocytoma): Report of a case and review of the literature. Diagnostic Cytopathology, 2014, 42, 242-246.	1.0	17
100	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Journal of the American College of Radiology, 2020, 17, 845-854.	1.8	17
101	Diagnostic approach to chronic dyspnoea in adults. Journal of Thoracic Disease, 2019, 11, S2117-S2128.	1.4	16
102	A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling. Cancer Discovery, 2014, 4, 1168-1181.	9.4	15
103	Lung cancer screening in Australia: progress or procrastination?. Medical Journal of Australia, 2016, 204, 4-5.	1.7	14
104	The effect of different radiological models on diagnostic accuracy and lung cancer screening performance. Thorax, 2017, 72, 1147-1150.	5.6	14
105	Primary Thoracic Cancers Incidentally Detected on CT Attenuation Correction Images During Myocardial Perfusion Scintigraphy. Clinical Lung Cancer, 2018, 19, e575-e579.	2.6	14
106	The cytotoxic, inflammatory and oxidative potential of coconut oil-substituted diesel emissions on bronchial epithelial cells at an air-liquid interface. Environmental Science and Pollution Research, 2019, 26, 27783-27791.	5.3	14
107	The effect of diesel emission exposure on primary human bronchial epithelial cells from a COPD cohort: N-acetylcysteine as a potential protective intervention. Environmental Research, 2019, 170, 194-202.	7.5	14
108	Cognitive behavioural therapy (CBT) for patients with chronic lung disease and psychological comorbidities undergoing pulmonary rehabilitation. Journal of Thoracic Disease, 2019, 11, S2238-S2253.	1.4	13

#	Article	IF	CITATIONS
109	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	1.1	13
110	Personalizing and targeting therapy for COPD – the role of molecular and clinical biomarkers. Expert Review of Respiratory Medicine, 2013, 7, 593-605.	2.5	12
111	Update in lung cancer: Prologue to a modern review series. Respirology, 2015, 20, 183-184.	2.3	12
112	Evaluation of an innovative mobile health programme for the self-management of chronic obstructive pulmonary disease (MH-COPD): protocol of a randomised controlled trial. BMJ Open, 2019, 9, e025381.	1.9	12
113	Primary human bronchial epithelial cell responses to diesel and biodiesel emissions at an air-liquid interface. Toxicology in Vitro, 2019, 57, 67-75.	2.4	12
114	Interstitial lung abnormalities in the Queensland Lung Cancer Screening Study: prevalence and progression over 2 years of surveillance. Internal Medicine Journal, 2019, 49, 843-849.	0.8	12
115	Air Pollution in the Asia-Pacific Region. A Joint Asian Pacific Society of Respirology/American Thoracic Society Perspective. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 693-700.	5.6	11
116	Human papollomavirus not found in squamous and large cell lung carcinomas by polymerase chain reaction. Cancer, 1995, 75, 2400-2401.	4.1	10
117	Associations between lung function and future cardiovascular morbidity and overall mortality in a predominantly First Nations population: a cohort study The Lancet Regional Health - Western Pacific, 2021, 13, 100188.	2.9	10
118	β <sub>2</sub> â€ADRENOCEPTOR POLYMORPHISMS AND OBSTRUCTIVE AIRWAY DISEASES: IMPORTANT ISSUI OF STUDY DESIGN. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 1029-1036.	ES <sub>1.9</sub>	9
119	Somatic mutations and immune checkpoint biomarkers. Respirology, 2019, 24, 215-226.	2.3	9
120	Cost of screening for lung cancer in Australia. Internal Medicine Journal, 2019, 49, 1392-1399.	0.8	8
121	Lung pathology: the molecular genetics of non-small cell lung cancer. Pathology, 1995, 27, 295-301.	0.6	7
122	Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulmonary Medicine, 2012, 12, 25.	2.0	7
123	RE: Proportion of Never-Smoker Non–Small Cell Lung Cancer Patients at Three Diverse Institutions. Journal of the National Cancer Institute, 2018, 110, 432-432.	6.3	7
124	Diagnosis of the cause of chronic dyspnoea in primary and tertiary care: characterizing diagnostic confidence. Journal of Thoracic Disease, 2018, 10, 3745-3756.	1.4	7
125	Optimizing lung cancer MDT data for maximum clinical impact—a scoping literature review. Translational Lung Cancer Research, 2020, 9, 1629-1638.	2.8	7
126	A Randomized Controlled Trial of a Non-pharmacological Intervention for Cancer-Related Dyspnea. Frontiers in Oncology, 2020, 10, 591610.	2.8	7

#	Article	IF	CITATIONS
127	Alternative methods for local ablation—interventional pulmonology: a narrative review. Translational Lung Cancer Research, 2021, 10, 3432-3445.	2.8	7
128	Role of TSG101 in Uterine Cervix Cancer. Gynecologic Oncology, 1999, 75, 401-405.	1.4	6
129	Lung Asbestos Content in Lungs Resected for Primary Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 569-576.	1.1	6
130	Clinical impact of data feedback at lung cancer multidisciplinary team meetings: A mixed methods study. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 45-55.	1.1	6
131	World Lung Day: what, why, and where to?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L527-L533.	2.9	6
132	Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	1.1	6
133	Leeuwenhoek's disease: diaphragmatic flutter in a cardiac patient. Cardiology in the Young, 2010, 20, 334-336.	0.8	5
134	Update in lung cancer: epilogue to a modern review series. Respirology, 2016, 21, 789-790.	2.3	5
135	Highâ€ <b>f</b> isk respiratory patients' experiences of bronchoscopy with conscious sedation and analgesia: A qualitative study. Journal of Clinical Nursing, 2018, 27, 2740-2751.	3.0	5
136	Determinants and Follow-up of Lung Function Data from a Predominantly First Nations Cohort of Adults Referred to Specialist Respiratory Outreach Clinics in Regional and Remote Queensland. Lung, 2021, 199, 417-425.	3.3	5
137	Cancer screening in Australia: future directions in melanoma, Lynch syndrome, and liver, lung and prostate cancers. Public Health Research and Practice, 2019, 29, .	1.5	5
138	Peripheral compartment innate immune response to <i>Haemophilus influenzae</i> and <i>Streptococcus pneumoniae</i> in chronic obstructive pulmonary disease patients. Innate Immunity, 2013, 19, 428-437.	2.4	4
139	Endobronchial Silicosis and Tuberculosis Presenting as the Right Middle Lobe Syndrome. Journal of Bronchology and Interventional Pulmonology, 2016, 23, e35-e37.	1.4	4
140	Potential clinical utility of multiple target quantitative polymerase chain reaction (qPCR) array to detect microbial pathogens in patients with chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2019, 11, S2254-S2265.	1.4	4
141	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
142	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
143	The Molecular Basis of Lung Carcinogenesis. , 2002, , 379-405.		4
144	Diagnosis and treatment of early lung cancer. Australian Journal of General Practice, 2020, 49, 508-512.	0.8	4

#	Article	IF	CITATIONS
145	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 0, , .	2.8	3
146	Low tumour cell content in a lung tumour bank: implications for molecular characterisation. Pathology, 2017, 49, 611-617.	0.6	3
147	Subtype variation and actionability of telomere length abnormality in lung cancer. Translational Lung Cancer Research, 2018, 7, S251-S253.	2.8	3
148	A Targeted Approach to the Complications of Targeted Therapy. Journal of Thoracic Oncology, 2019, 14, 577-579.	1.1	3
149	Germline <i>ERBB3</i> mutation in familial non-small-cell lung carcinoma: expanding ErbB's role in oncogenesis. Human Molecular Genetics, 2021, 30, 2393-2401.	2.9	3
150	EGFR Mutation Testing in Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2010, 6, 310-321.	0.2	2
151	Personalized medicine for lung cancer. Lung Cancer Management, 2012, 1, 83-86.	1.5	2
152	Electromagnetic navigation bronchoscopy for the diagnosis of <scp> <i>A</i> </scp> <i>spergillus</i> infection. Respirology Case Reports, 2014, 2, 30-32.	0.6	2
153	Genomics of lung cancer. Journal of Thoracic Disease, 2017, 9, E155-E157.	1.4	2
154	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. Journal of Thoracic Disease, 2018, 10, 3883-3890.	1.4	2
155	Clinical management practices of life-threatening asthma: an audit of practices in intensive care. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 53-62.	0.1	2
156	Lung cancer screening—Marching along …. Respirology, 2022, 27, 578-580.	2.3	2
157	Hospitalâ€activity data inaccurate for determining spreadâ€ofâ€disease at diagnosis for nonâ€small cell lung cancer. Australian and New Zealand Journal of Public Health, 2012, 36, 212-217.	1.8	1
158	Glycopyrronium bromide for chronic obstructive pulmonary disease. The Cochrane Library, 2013, , .	2.8	1
159	P1.05-015 Genomic Characterization of Non-Small Cell Lung Cancer in an Australian Population. Journal of Thoracic Oncology, 2017, 12, S622-S623.	1.1	1
160	Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma. The Cochrane Library, 2017, , .	2.8	1
161	Is Digital Tomosynthesis on Par With Computed Tomography for the Detection and Measurement of Pulmonary Nodules?. Journal of Thoracic Imaging, 2017, 32, W67-W68.	1.5	1
162	Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles. Annals of Translational Medicine, 2021, 9, 586-586.	1.7	1

#	Article	IF	CITATIONS
163	Optimal use of advanced technology. Expert Review of Respiratory Medicine, 2009, 3, 9-11.	2.5	0
164	Digital tomosynthesis for the detection and management of pulmonary nodules. Lung Cancer Management, 2013, 2, 5-7.	1.5	0
165	The potential of genome-wide analyses to improve non-small-cell lung cancer care. Lung Cancer Management, 2014, 3, 383-396.	1.5	0
166	General medicine Indigenous outreach registrar training in rural Queensland. Medical Journal of Australia, 2016, 205, 237-237.	1.7	0
167	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. The Cochrane Library, 2017, , .	2.8	0
168	Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6.		0
169	Editorial on PanCan study. Translational Lung Cancer Research, 2018, 7, S57-S59.	2.8	0
170	Incidental Pulmonary Malignancies on CTAC in MPS. Clinical Lung Cancer, 2018, 19, e801-e802.	2.6	0
171	EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 2019, 7, S326-S326.	1.7	0
172	Overview of Lung Cancer. , 2022, , 621-633.		0
173	Should we screen for lung cancer in Australia?. Medical Journal of Australia, 2013, 199, 585-586.	1.7	0
174	Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FDG-PET staging Journal of Clinical Oncology, 2019, 37, e20045-e20045.	1.6	0
175	The current and future roles of genomics. , 0, , 79-94.		0
176	Lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S452-3.	1.4	0